The ACC Preclinical Research Platform for Precision Oncology

Launched by FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA · Mar 25, 2024

Keywords

ClinConnect Summary

The ACC Preclinical Research Platform for Precision Oncology is a clinical trial designed to better understand and treat different types of cancers, including solid tumors and blood cancers. The goal of this study is to use special models created from patients' own tumor tissues or cells, called Patient Derived Cancer Models (PDCM). By doing this, researchers hope to learn more about how these tumors behave and to test how effective different treatments might be for each patient.

This trial is open to patients of all ages, including children, who have solid tumors or blood cancers and have available tumor tissue or cells. There are no specific exclusions, meaning most patients with the right samples can participate. If you join this study, you can expect to contribute to important research that could lead to more personalized and effective cancer treatments in the future. Your involvement might help improve our understanding of cancer and how to fight it better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients, including paediatric patients, with solid and haematological malignancies for whom tissue or tumour cell material is available.
• Exclusion Criteria:
• • none